%D9%BE%DB%86%D9%85%D8%A7%D9%84%DB%8C%D8%AF%DB%86%D9%85%D8%A7%DB%8C%D8%AFCategory:PomalidomidePomalidomidPomalidomidePomalidomida%D9%BE%D9%88%D9%85%D8%A7%D9%84%DB%8C%D8%AF%D9%88%D9%85%D8%A7%DB%8C%D8%AF%E3%83%9D%E3%83%9E%E3%83%AA%E3%83%89%E3%83%9F%E3%83%89%D0%9F%D0%BE%D0%BC%D0%B0%D0%BB%D0%B8%D0%B4%D0%BE%D0%BC%D0%B8%D0%B4PomalidomidPomalidomidPomalidomideQ7227206
about
sameAs
P3355
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaPomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaEvaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaPomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionPomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansPomalidomide and Dexamethasone (PDex) in AL AmyloidosisA Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple MyelomaACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaEfficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Multi-Center Study of GSK2857916 in Combination With Pomalidomide and DexIPD in RRMM Characterized With Genomic Abnormalities of Adverse PrognosticSafety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple MyelomaA Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaAn Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaStudy of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaA Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL AmyloidosisStudy of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung DiseaseOpen-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple MyelomaStudy to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell DiseaseFilgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple MyelomaA Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male SubjectsA Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaA Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and RefracAlternate Day Dosing of Pomalidomide in Patients With Refractory Multiple MyelomaA Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaStudy of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaA Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple MyelomaTEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple MyelomaPomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsA Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple MyelomaPomalidomide for the Treatment of Bleeding in HHTAn Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesNivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaCarfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple MyelomaMyeloma-Developing Regimens Using Genomics (MyDRUG)Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide: A Study in Relapsed or Refractory Multiple MyelomaExpanded Access for CC-4047
P4844
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideImmunomodulatory agents in myelofibrosis.Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.Immunomodulatory drugs in multiple myeloma.Novel therapeutics in multiple myeloma.Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugsThalidomide and its analogues in the treatment of Multiple MyelomaManagement of myeloproliferative neoplasms: from academic guidelines to clinical practice.Breakthroughs in myeloproliferative neoplasms.Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.Novel immunomodulatory compounds in multiple myeloma.Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.Phase I trial of pomalidomide given for patients with advanced solid tumors.Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.Targeted therapy of multiple myeloma.Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaPomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansPomalidomide and Dexamethasone (PDex) in AL AmyloidosisACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaStudy of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple MyelomaStudy to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell DiseaseA Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male SubjectsA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple MyelomaA Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and RefracAlternate Day Dosing of Pomalidomide in Patients With Refractory Multiple MyelomaA Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaStudy of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaTEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple MyelomaPomalidomide for the Treatment of Bleeding in HHTDaratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple MyelomaLong-term outcome of pomalidomide therapy in myelofibrosisPomalidomide is effective for prevention and treatment of experimental skin fibrosis
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Pomalidomid
@de
Pomalidomid
@sh
Pomalidomid
@sr
Pomalidomida
@es
Pomalidomide
@vi
pomalidomid
@nn
pomalidomide
@en
Помалидомид
@ru
پومالیدوماید
@fa
پۆمالیدۆماید
@ckb
type
label
Pomalidomid
@de
Pomalidomid
@sh
Pomalidomid
@sr
Pomalidomida
@es
Pomalidomide
@vi
pomalidomid
@nn
pomalidomide
@en
Помалидомид
@ru
پومالیدوماید
@fa
پۆمالیدۆماید
@ckb
altLabel
3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide
@en
4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione
@en
4-Aminothalidomide
@en
CC 4047
@en
CC-4047
@en
IMID-3
@en
Imnovid®
@en
Pomalidomide
@en
Pomalyst®
@en
prefLabel
Pomalidomid
@de
Pomalidomid
@sh
Pomalidomid
@sr
Pomalidomida
@es
Pomalidomide
@vi
pomalidomid
@nn
pomalidomide
@en
Помалидомид
@ru
پومالیدوماید
@fa
پۆمالیدۆماید
@ckb